RayKnowChina Research Map
Shortlist

WuhanHuazhong Univ. of Sci. & Tech. – Tongji Medical College

Tongji Hospital

华中科技大学同济医学院附属同济医院

Listed for 41 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Tongji Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led2 open trials led
  3. Hepatocellular carcinoma肝细胞癌238 papers led23 open trials led
  4. Stomach cancer胃癌45 papers led4 open trials led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Retinoblastoma视网膜母细胞瘤1 paper led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤12 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led1 open trial led
  10. Neuroblastoma神经母细胞瘤8 papers led
  11. Ewing sarcoma尤文肉瘤0 papers led
  12. Multiple myeloma多发性骨髓瘤19 papers led3 open trials led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病7 papers led1 open trial led
  14. Aplastic anaemia再生障碍性贫血8 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症20 papers led1 open trial led
  16. Beta thalassaemiaβ 地中海贫血0 papers led
  17. Haemophilia A血友病 A4 papers led
  18. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜6 papers led
  19. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病18 papers led7 open trials led
  20. IgG4-related diseaseIgG4相关性疾病11 papers led2 open trials led
  21. Myasthenia gravis重症肌无力17 papers led8 open trials led
  22. Moyamoya disease烟雾病3 papers led1 open trial led
  23. Biliary atresia胆道闭锁2 papers led1 open trial led
  24. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化14 papers led
  26. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  27. Amyotrophic lateral sclerosis肌萎缩侧索硬化症11 papers led1 open trial led
  28. Fabry disease法布雷病0 papers led
  29. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  30. Behçet disease白塞病1 paper led
  31. Alport syndromeAlport 综合征2 papers led
  32. IgA nephropathyIgA 肾病21 papers led
  33. Gaucher disease戈谢病0 papers led
  34. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  35. Osteogenesis imperfecta成骨不全症0 papers led
  36. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  37. Hirschsprung disease先天性巨结肠13 papers led
  38. Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
  39. Hereditary angioedema遗传性血管性水肿1 paper led
  40. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
  41. Leber hereditary optic neuropathyLeber 遗传性视神经病变2 papers led

Not listed for: Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Takayasu arteritis, Hepatic echinococcosis, Spinal muscular atrophy, Pompe disease, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 2220232024: 1120242025: 002025

6 hospitals in Wuhan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  2. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  3. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  4. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgeryNeurology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.2024PeerJFree full text
  2. Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment.2023Journal of immunology researchFree full text
  3. Ginsenoside Rg3 Sensitizes Nasopharyngeal Carcinoma Cells to Radiation by Suppressing Epithelial Mesenchymal Transition.2023Radiation research
  4. CircSOX9 acts as a molecular sponge of miR-485-3p to promote the progression of nasopharyngeal carcinoma.2022AgingFree full text
  5. MEX3A promotes nasopharyngeal carcinoma progression via the miR-3163/SCIN axis by regulating NF-κB signaling pathway.2022Cell death & diseaseFree full text
  6. MiR196a-5p in extracellular vesicles released from human nasopharyngeal carcinoma enhance the phagocytosis and secretion of microglia by targeting ROCK1.2022Experimental cell research
  7. Inhibition of PDK1 enhances radiosensitivity and reverses epithelial-mesenchymal transition in nasopharyngeal carcinoma.2022Head & neck
  8. Induction of interleukin-6 by irradiation and its role in epithelial mesenchymal transition and radioresistance of nasopharyngeal carcinoma cells.2021Head & neck
All its trials on ClinicalTrials.gov, any status14
  1. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  2. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  3. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  4. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  5. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  6. KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical TrialStatus unknownNCT06097793Study siteEarly phase 1Start 2023-12
  7. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Study sitePhase 3Start 2023-09
  8. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  9. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  10. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  12. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  13. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
  14. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRTStatus unknownNCT01817023Study sitePhase 3Start 2013-04
More papers found outside PubMed (not counted)6
  1. Development and Validation of a Multi‐Omics Model Integrating MR Radiomics and Immune Scores for Prognostic Prediction in Locally Advanced Nasopharyngeal Carcinoma2025Flavour and Fragrance Journalarticle
  2. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  3. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  4. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  5. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  6. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 5520232024: 0020242025: 112025

5 hospitals in Wuhan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07088354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT07699185

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyMolecular markers & genomics
Departments in papersMedical oncology
Papers it led10
  1. Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  2. SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop.2023Cell death & diseaseFree full text
  3. BBOX1-AS1 Activates Hedgehog Signaling Pathway to Facilitate the Proliferation and Stemness of Esophageal Squamous Cell Carcinoma Cells via miR-506-5p/EIF5A/PTCH1 Axis.2023Current molecular pharmacology
  4. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.2023Frontiers in immunologyFree full text
  5. Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184.2023Genomics
  6. Diagnosis and treatment of right ventricular metastasis from esophageal squamous cell carcinoma: An unusual case report and a literature review.2023MedicineFree full text
  7. Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer.2022CellsFree full text
  8. Esophagus cancer and essential trace elements.2022Frontiers in public healthFree full text
  9. GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis.2022OncogeneFree full text
  10. An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases: A case report and overview of the literature.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant ImmunochemotherapyRecruitingNCT07088354Lead sponsorStart 2025-03
  2. Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07699185Lead sponsorPhase 2Start 2024-01
  3. Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT07705412Lead sponsorStart 2025-09
  4. Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical StudyStatus unknownNCT05028231Lead sponsorStart 2021-06
  5. Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06165380Lead (inferred)Phase 2Start 2023-10
  6. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  7. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  8. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  9. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12
More papers found outside PubMed (not counted)15
  1. Tislelizumab combined with radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II study (TREC)2025Research Squarepreprint
  2. Letter to the Editor: Human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy2024Venue not listedpreprint
  3. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  4. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells2023European surgery. Supplement/European surgeryarticle
  9. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  13. Design and synthesis of copper nanoparticles for the treatment of human esophageal cancer: introducing a novel chemotherapeutic supplement2022Journal of Experimental Nanosciencearticle
  14. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  15. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 238 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.6%.

Papers led
238
2021–2025
Trials led
51
any status, ClinicalTrials.gov
Open trials led
23
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 424220212022: 373720222023: 545420232024: 444420242025: 54542025

6 hospitals in Wuhan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 30

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07413354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT06954116

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  3. Recruiting
    AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07062380

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  4. Recruiting
    Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07154082

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Registry
    NCT07282184

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  6. Recruiting
    Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06280313

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  7. Recruiting
    Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
    Phase
    Phase 4
    Started
    2024-04
    Registry
    NCT06311929

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  8. Recruiting
    Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06470256

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  9. Recruiting
    Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06653062

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  10. Recruiting
    Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT07838415

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  11. Recruiting
    HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06187961

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  12. Recruiting
    Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05520788

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  13. Not yet recruiting
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07537946

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  14. Not yet recruiting
    Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07537959

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  15. Not yet recruiting
    Denosumab Strategy for Liver Cancer With Bone Metastases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07537972

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  16. Not yet recruiting
    AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07729618

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  17. Not yet recruiting
    AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07732504

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  18. Not yet recruiting
    QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06822985

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  19. Not yet recruiting
    Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06896396

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  20. Not yet recruiting
    Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07064668

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  21. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

  22. Not yet recruiting
    Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07350824

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  23. Not yet recruiting
    Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06089369

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  24. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  25. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  26. Recruiting
    cfDNA Methylation for Liver Cancer Recurrence Detection
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07466602

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  27. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  28. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  29. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  30. Enrolling by invitation
    A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05441475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led238
  1. Long-Term Survival and Beneficiaries of Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma.2026Annals of surgical oncology
  2. Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets.2026Biochimica et biophysica acta. Reviews on cancer
  3. Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma.2026Cancer treatment and research communications
  4. NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma.2026Hepatology (Baltimore, Md.)Free full text
  5. Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.2026International journal of surgery (London, England)
  6. Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma.2026Journal of advanced researchFree full text
  7. A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.2026Science China. Life sciences
  8. Hafnium Metal-Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  9. m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by Facilitating the Membrane Translocation and Activation of AKT.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. CKAP4 in hepatocellular carcinoma: competitive RETREG1/FAM134B binding, reticulophagy regulation, and cancer progression.2025AutophagyFree full text
  11. Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.2025BJS openFree full text
  12. Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study.2025BJS openFree full text
  13. From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy.2025BMC cancerFree full text
  14. Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.2025BMJ openFree full text
  15. The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer.2025Biochimica et biophysica acta. Reviews on cancer
  16. Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2025Bioorganic chemistry
  17. Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation.2025Cancer biology & therapyFree full text
  18. FBXO22 promotes HCC angiogenesis and metastasis via RPS5/AKT/HIF-1α/VEGF-A signaling axis.2025Cancer gene therapyFree full text
  19. Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma.2025Cell communication and signaling : CCSFree full text
  20. The cancer-associated fibroblast facilitates YAP liquid-liquid phase separation to promote cancer cell stemness in HCC.2025Cell communication and signaling : CCSFree full text
  21. Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  22. The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.2025Cell death & diseaseFree full text
  23. IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  24. Disrupting CCDC137-mediated LZTS2 and β-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via β-catenin and AKT.2025Cell death and differentiationFree full text
  25. Cancer-associated fibroblast-derived extracellular vesicles facilitate metastasis in hepatocellular carcinoma by delivering CTGF.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  26. Ribosomal protein L6 suppresses hepatocellular carcinoma by modulating FBXO22-mediated p53 degradation.2025Cellular signalling
  27. Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma.2025Clinical and molecular hepatologyFree full text
  28. MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation.2025Clinical and molecular hepatologyFree full text
  29. Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma.2025Clinical and translational medicineFree full text
  30. Machine Learning-based Gene Biomarker Identification for Improving Prognosis and Therapy in Hepatocellular Carcinoma.2025Current medicinal chemistry
  31. Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma.2025Digestive diseases and sciencesFree full text
  32. Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy.2025European journal of medical researchFree full text
  33. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma.2025European journal of nuclear medicine and molecular imaging
  34. Differentiating atypical hepatocellular carcinoma from focal nodular Hyperplasia: The value of Kupffer phase imaging with Sonazoid-Contrast-Enhanced ultrasound compared to Gadodiamide-Enhanced MRI.2025European journal of radiology
  35. Synchronous hepatectomy and splenectomy for patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension: A multicenter retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  36. Efficacy and safety of preoperative TACE in hepatocellular carcinoma beyond Milan criteria: A propensity score matching analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  37. An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  38. Post-translational acylation modulates immunosuppression and immunotherapy efficacy in hepatocellular carcinoma.2025Genes and immunity
  39. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.2025Gut
  40. The impact of resection margin width on surgical outcomes for solitary hepatocellular carcinoma with sub-classification of microvascular invasion.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  41. Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.2025Hepatology (Baltimore, Md.)Free full text
  42. Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma.2025Hepatology international
  43. Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota.2025International journal of biological sciencesFree full text
  44. Association between Vessels Encapsulating Tumor Clusters and Circulating Tumor Cells in Hepatocellular Carcinoma: Clinical Evidence and Risk Model Development.2025International journal of medical sciencesFree full text
  45. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.2025Journal of hepatology
  46. EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.2025Journal of molecular histology
  47. Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases.2025Journal of molecular medicine (Berlin, Germany)Free full text
  48. Synthesis and Preclinical Evaluation of Dual-Specific Probe Targeting Glypican-3 and Prostate-Specific Membrane Antigen for Hepatocellular Carcinoma PET Imaging.2025Molecular pharmaceutics
  49. 18F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma.2025Molecular pharmaceutics
  50. VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.2025Nature communicationsFree full text
  51. Circ-PAN3 facilitates hepatocellular carcinoma growth via sponging miR-153 and upregulating cyclin D1.2025Oncology researchFree full text
  52. Overexpression of ORAOV1 and its association with immunotherapy resistance in hepatocellular carcinoma.2025PeerJFree full text
  53. Perfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma.2025Radiology. Imaging cancerFree full text
  54. PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.2025Redox biologyFree full text
  55. Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma.2025Science immunology
  56. Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China.2025The oncologistFree full text
  57. 18F-5-fluoro-aminosuberic acid PET/CT imaging of oxidative-stress features during the formation of DEN-induced rat hepatocellular carcinoma.2025TheranosticsFree full text
  58. Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies.2025World journal of surgical oncologyFree full text
  59. Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  60. Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.2025World journal of surgical oncologyFree full text
  61. Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  62. "Trinity" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO3@CuO2 Nanoparticles Induces "Cuproptosis" in HCC.2024ACS applied materials & interfaces
  63. CEUS in prediction of early recurrence of hepatocellular carcinoma after curative resection and to stratify the risk of early recurrence: a retrospective observational study.2024Abdominal radiology (New York)
  64. Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.2024Abdominal radiology (New York)
  65. Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  66. m6A-Dependent ITIH1 Regulated by TGF-β Acts as a Target for Hepatocellular Carcinoma Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  67. SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  68. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  69. Liver resection versus microwave ablation for solitary and small (≤ 3 cm) HCC with early recurrence in different stages of liver cirrhosis: A propensity score matching study.2024Asian journal of surgery
  70. A pathologic scoring system for predicting postoperative prognosis in patients with ruptured hepatocellular carcinoma.2024Asian journal of surgery
  71. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  72. Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.2024Cancer communications (London, England)Free full text
  73. GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway.2024Cell death & diseaseFree full text
  74. TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion.2024Cell death & diseaseFree full text
  75. HMGB1 promotes mitochondrial transfer between hepatocellular carcinoma cells through RHOT1 and RAC1 under hypoxia.2024Cell death & diseaseFree full text
  76. Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma.2024Cell host & microbe
  77. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma.2024Chinese medical journalFree full text
  78. SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation.2024Clinical and translational medicineFree full text
  79. Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma.2024Computers in biology and medicine
  80. A Randomized Comparison of Transradial and Transfemoral Approach in Hepatic Arterial Infusion Chemotherapy.2024Current medical imagingRCT
  81. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.2024Drug discovery today
  82. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.2024EBioMedicineFree full text
  83. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.2024Frontiers in immunologyFree full text
  84. Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  85. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.2024Gastroenterology
  86. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.2024GutFree full text
  87. Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity.2024Hepatology international
  88. The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma.2024Immunology
  89. SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy.2024International immunopharmacology
  90. SLC41A1 overexpression correlates with immune cell infiltration in HCC and promotes its malignant progression.2024International journal of medical sciencesFree full text
  91. The Prognostic and Therapeutic Roles of ARL-6 Gene in Hepatocellular Carcinoma.2024International journal of medical sciencesFree full text
  92. Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.2024International journal of oncologyFree full text
  93. Contradictory Role of Gadd45β in Liver Diseases.2024Journal of cellular and molecular medicineFree full text
  94. Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  95. N6-methyladenosine modification of circular RNA circASH2L suppresses growth and metastasis in hepatocellular carcinoma through regulating hsa-miR-525-3p/MTUS2 axis.2024Journal of translational medicineFree full text
  96. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.2024La Radiologia medica
  97. Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report.2024MedicineFree full text
  98. USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling.2024Nature communicationsFree full text
  99. Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.2024Pathogens (Basel, Switzerland)Free full text
  100. NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma.2024Scientific reportsFree full text
  101. Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.2024Surgical endoscopy
  102. Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection.2024TheranosticsFree full text
  103. Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment.2024Trends in endocrinology and metabolism: TEM
  104. Comparison of Sonazoid-Contrast‑Enhanced Ultrasound and Gd‑EOB‑DTPA‑Enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  105. Is ALPPS still appropriate for large or locally advanced hepatocellular carcinoma in an era of targeted agents and immunotherapy?2024Updates in surgery
  106. Core-shell cisplatin/SiO2 nanocapsules combined with PTC-209 overcome chemotherapy-Acquired and intrinsic resistance in hepatocellular carcinoma.2023Acta biomaterialia
  107. Bone Lesion-Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5-Targeting miR-3190-5p.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  108. A Prospective Study Using Propensity Score Matching to Compare Long-term Survival Outcomes After Robotic-assisted, Laparoscopic, or Open Liver Resection for Patients With BCLC Stage 0-A Hepatocellular Carcinoma.2023Annals of surgery
  109. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2023BMC cancerFree full text
  110. MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2.2023BMC cancerFree full text
  111. Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.2023BMC cancerFree full text
  112. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  113. Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.2023Cancer letters
  114. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.2023Cell death and differentiationFree full text
  115. The role of pyroptosis in hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  116. LINC01980 induced by TGF-beta promotes hepatocellular carcinoma metastasis via miR-376b-5p/E2F5 axis.2023Cellular signalling
  117. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.2023Clinics and research in hepatology and gastroenterology
  118. Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect.2023Critical reviews in oncology/hematology
  119. Scientific Hepatectomy for Hepatocellular Carcinoma.2023Current medical science
  120. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.2023Current medical science
  121. Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.2023Current medical science
  122. Long noncoding RNA MAPKAPK5-AS1 promotes metastasis through regulation miR-376b-5p/ECT2 axis in hepatocellular carcinoma.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  123. A nomogram for preoperative prediction of microvascular invasion in ruptured hepatocellular carcinoma.2023European journal of gastroenterology & hepatology
  124. Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  125. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact?2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  126. Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  127. HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.2023European radiology
  128. Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.2023Frontiers in immunologyFree full text
  129. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody fol2023Frontiers in immunologyFree full text
  130. Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.2023Frontiers in immunologyFree full text
  131. Identification of molecular pattern and prognostic risk model based on ligand-receptor pairs in liver cancer.2023Frontiers in immunologyFree full text
  132. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.2023Frontiers in immunologyFree full text
  133. Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.2023Frontiers in immunologyFree full text
  134. Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors.2023Frontiers in immunologyFree full text
  135. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  136. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.2023Genetics researchFree full text
  137. Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  138. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.2023Hepatology (Baltimore, Md.)Free full text
  139. Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.2023Hepatology (Baltimore, Md.)Free full text
  140. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.2023International immunopharmacology
  141. CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1.2023International journal of biological sciencesFree full text
  142. Comprehensive Analysis of Sideroflexin 4 in Hepatocellular Carcinoma by Bioinformatics and Experiments.2023International journal of medical sciencesFree full text
  143. Histone H3 activates caspase-1 and promotes proliferation and metastasis in hepatocellular carcinoma.2023International journal of medical sciencesFree full text
  144. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.2023Journal of cancer research and clinical oncologyFree full text
  145. Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis.2023Journal of cancer research and clinical oncologyFree full text
  146. Risk Factors of Positive Resection Margin in Hepatectomy for Resectable Ruptured Hepatocellular Carcinoma: Risk Prediction and Prognosis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  147. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.2023Journal of hematology & oncologyFree full text
  148. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.2023Journal of hepatology
  149. The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma.2023Journal of translational medicineFree full text
  150. LINC01608 activated by YY1 facilitate hepatocellular carcinoma progression by modulating the EGFR/ERK axis.2023Liver international : official journal of the International Association for the Study of the Liver
  151. Intelectin-1 is a novel prognostic biomarker for hepatocellular carcinoma.2023MedicineFree full text
  152. MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma.2023Oncogene
  153. A micropeptide JunBP regulated by TGF-β promotes hepatocellular carcinoma metastasis.2023OncogeneFree full text
  154. Diagnostic Value of OPNI in Hepatocellular Carcinoma.2023Oncology
  155. The correlation between tumor-associated macrophages and the prognosis of east Asian hepatocellular carcinoma patients: A systematic review and meta-analysis.2023Pathology, research and practice
  156. Targeting super enhancers for liver disease: a review.2023PeerJFree full text
  157. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.2023Scientific reportsFree full text
  158. Dynamic contrast-enhanced ultrasonography with sonazoid predicts microvascular invasion in early-stage hepatocellular carcinoma.2023The British journal of radiologyFree full text
  159. MYC-activated LINC00607 promotes hepatocellular carcinoma progression by regulating the miR-584-3p/ROCK1 axis.2023The journal of gene medicine
  160. Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma.2022AgingFree full text
  161. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  162. The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy.2022BMC surgeryFree full text
  163. Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  164. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.2022Cancer communications (London, England)Free full text
  165. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression.2022Cancer scienceFree full text
  166. Cell adhesion molecule BVES functions as a suppressor of tumor cells extrusion in hepatocellular carcinoma metastasis.2022Cell communication and signaling : CCSFree full text
  167. ALKBH5-mediated m6A modification of lincRNA LINC02551 enhances the stability of DDX24 to promote hepatocellular carcinoma growth and metastasis.2022Cell death & diseaseFree full text
  168. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.2022Cell death & diseaseFree full text
  169. Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation.2022Cell death and differentiationFree full text
  170. Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma.2022CellsFree full text
  171. Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling.2022Cellular & molecular biology lettersFree full text
  172. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  173. Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A.2022Clinical and translational medicineFree full text
  174. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.2022Current medical imaging
  175. Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child-Pugh A.2022Current oncology (Toronto, Ont.)Free full text
  176. Alpha-Fetoprotein+Alkaline Phosphatase (A-A) Score Can Predict the Prognosis of Patients with Ruptured Hepatocellular Carcinoma Underwent Hepatectomy.2022Disease markersFree full text
  177. Hepatectomy for ruptured hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer stage 0/A: The optimal treatment.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  178. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.2022European radiology
  179. Identifying potential pharmacological targets and mechanisms of vitamin D for hepatocellular carcinoma and COVID-19.2022Frontiers in immunologyFree full text
  180. Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis.2022Frontiers in immunologyFree full text
  181. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.2022Frontiers in immunologyFree full text
  182. Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives.2022Frontiers of medicine
  183. Pan-cancer analysis combined with experimental validation revealed IL4I1 as an immunological and prognostic biomarker.2022International immunopharmacology
  184. Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma.2022International journal of cancer
  185. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.2022Irish journal of medical science
  186. TRIM proteins in hepatocellular carcinoma.2022Journal of biomedical scienceFree full text
  187. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET.2022Journal of experimental & clinical cancer research : CRFree full text
  188. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway.2022Journal of experimental & clinical cancer research : CRFree full text
  189. T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.2022Oncogene
  190. DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6.2022OncogeneFree full text
  191. DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  192. Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis.2022Surgical endoscopy
  193. 18[Formula: see text]-Glycyrrhetinic Acid Inhibits TGF-[Formula: see text]-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Targeting STAT3.2022The American journal of Chinese medicine
  194. Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2.2022TheranosticsFree full text
  195. Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number.2022World journal of gastroenterologyFree full text
  196. Ultrasound-based artificial intelligence in gastroenterology and hepatology.2022World journal of gastroenterologyFree full text
  197. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.2021Abdominal radiology (New York)
  198. Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study.2021Academic radiology
  199. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.2021AgingFree full text
  200. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma.2021AgingFree full text
  201. SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK.2021AgingFree full text
  202. Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma.2021AgingFree full text
  203. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.2021AgingFree full text
  204. Comment on "Sub-classification of Microscopic Vascular Invasion in Hepatocellular Carcinoma".2021Annals of surgery
  205. ASO Author Reflections: Collagen Contents of Liver Tissue Are Significantly Correlated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Hepatocellular Carcinoma Patients with Child-Pugh Grade A Liver Function.2021Annals of surgical oncology
  206. Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function.2021Annals of surgical oncology
  207. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.2021BioMed research internationalFree full text
  208. LncRNA influence sequential steps of hepatocellular carcinoma metastasis.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  209. LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  210. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.2021Cancer medicineFree full text
  211. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetopr2021Cancer medicineFree full text
  212. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.2021Cell death & diseaseFree full text
  213. Circular RNA circUBE2J2 acts as the sponge of microRNA-370-5P to suppress hepatocellular carcinoma progression.2021Cell death & diseaseFree full text
  214. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells.2021Cell death & diseaseFree full text
  215. GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.2021Clinical and translational medicineFree full text
  216. L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.2021Drug deliveryFree full text
  217. ESR1 mediated circ_0004018 suppresses angiogenesis in hepatocellular carcinoma via recruiting FUS and stabilizing TIMP2 expression.2021Experimental cell research
  218. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.2021Experimental cell research
  219. Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  220. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  221. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.2021Frontiers of medicine
  222. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.2021Hepatology (Baltimore, Md.)
  223. H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.2021Hepatology (Baltimore, Md.)
  224. HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma.2021International journal of medical sciencesFree full text
  225. Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma.2021Journal of cellular and molecular medicineFree full text
  226. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.2021Journal of experimental & clinical cancer research : CRFree full text
  227. Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression.2021Journal of experimental & clinical cancer research : CRFree full text
  228. FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.2021Journal of experimental & clinical cancer research : CRFree full text
  229. Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis.2021Journal of experimental & clinical cancer research : CRFree full text
  230. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.2021Journal of hepatologyFree full text
  231. Identification of MCM family as potential therapeutic and prognostic targets for hepatocellular carcinoma based on bioinformatics and experiments.2021Life sciences
  232. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.2021Molecular medicine reportsFree full text
  233. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy.2021Scientific reportsFree full text
  234. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.2021TheranosticsFree full text
  235. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.2021TheranosticsFree full text
  236. Acute graft-versus-host disease after liver transplantation in a close contact with COVID-19: A case report.2021Transplant immunologyFree full text
  237. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.2021Ultrasound in medicine & biology
  238. Author's Reply: Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma.2021World journal of surgery
Chinese-language papers (not in the count)1
  1. [Immunotherapy clinical application and research prospects for liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status73
  1. AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or AblationNot yet recruitingNCT07732504Lead sponsorN/AStart 2026-10
  2. Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingNCT07537972Lead sponsorPhase 2Start 2026-05
  3. Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic MetastasesNot yet recruitingNCT07537959Lead sponsorN/AStart 2026-04
  4. Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaRecruitingNCT07413354Lead sponsorPhase 2Start 2026-04
  5. AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07729618Lead sponsorN/AStart 2026-10
  6. Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingNCT07537946Lead sponsorPhase 3Start 2026-05
  7. Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCCNot yet recruitingNCT07350824Lead sponsorN/AStart 2025-12
  8. Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and InterventionRecruitingNCT07282184Lead sponsorPhase 1/Phase 2Start 2025-10
  9. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Lead sponsorPhase 2Start 2025-12
  10. Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective StudyNot yet recruitingNCT07064668Lead sponsorPhase 2Start 2025-07
  11. Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruitingNCT06954116Lead sponsorPhase 2Start 2025-08
  12. AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)RecruitingNCT07062380Lead sponsorStart 2025-06
  13. Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular InvasionNot yet recruitingNCT06089369Lead sponsorPhase 3Start 2024-06
  14. Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence SurveillanceRecruitingNCT06653062Lead sponsorStart 2024-11
  15. Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver CancerRecruitingNCT07838415Lead sponsorStart 2024-10
  16. HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Lead sponsorPhase 2Start 2023-12
  17. Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation SequencingRecruitingNCT05520788Lead sponsorStart 2020-05
  18. A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for RecurrenceActive, not recruitingNCT07009470Lead sponsorN/AStart 2025-02
  19. Precision Recurrence Risk Assessment in Early-stage Hepatocellular CarcinomaCompletedNCT07030842Lead sponsorStart 2023-08
  20. A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionStatus unknownNCT06089382Lead sponsorPhase 3Start 2023-11
  21. Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaStatus unknownNCT05717738Lead sponsorStart 2022-01
  22. Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular CarcinomaActive, not recruitingNCT07444905Lead sponsorStart 2022-02
  23. PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver CancerStatus unknownNCT05103007Lead sponsorN/AStart 2021-12
  24. Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCCStatus unknownNCT05420922Lead sponsorStart 2021-11
  25. Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular CarcinomaCompletedNCT05178524Lead sponsorN/AStart 2021-06
  26. Primary Hepatobiliary Cancer Cohort of Central ChinaStatus unknownNCT05520801Lead sponsorStart 2020-05
  27. The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort StudyCompletedNCT07639294Lead sponsorStart 2018-06
  28. The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular CarcinomaCompletedNCT04303286Lead sponsorStart 2018-10
  29. Circulating Tumor Cell Detection in Hepatocellular CarcinomaCompletedNCT05297955Lead sponsorStart 2013-11
  30. Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06896396Lead (inferred)Phase 1/Phase 2Start 2025-04
  31. Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular CarcinomaRecruitingNCT07154082Lead (inferred)Phase 2Start 2025-12
  32. QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular CarcinomaNot yet recruitingNCT06822985Lead (inferred)Phase 1Start 2025-02
  33. Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal HypertensionRecruitingNCT06280313Lead (inferred)Start 2024-03
  34. Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Lead (inferred)Phase 1Start 2024-06
  35. Precision Adjuvant Therapy After Surgery for Hepatocellular CarcinomaRecruitingNCT06311929Lead (inferred)Phase 4Start 2024-04
  36. A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCStatus unknownNCT05839197Lead (inferred)Phase 2Start 2023-05
  37. Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCStatus unknownNCT05533892Lead (inferred)Phase 1Start 2022-09
  38. Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular CarcinomaCompletedNCT06776185Lead (inferred)Start 2022-01
  39. Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave AblationCompletedNCT06248554Lead (inferred)N/AStart 2021-01
  40. Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular CarcinomaStatus unknownNCT05031949Lead (inferred)Phase 1Start 2021-10
  41. ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma RuptureCompletedNCT06102278Lead (inferred)Start 2020-01
  42. Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular CarcinomaStatus unknownNCT04076631Lead (inferred)Start 2019-08
  43. Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular CarcinomaStatus unknownNCT03881501Lead (inferred)Start 2019-03
  44. Postoperative Adjuvant Therapy of HCC Based on PD-1CompletedNCT05307926Lead (inferred)Start 2019-02
  45. Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCCStatus unknownNCT06461936Lead (inferred)Start 2019-01
  46. Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic ModellingCompletedNCT06298123Lead (inferred)Start 2019-02
  47. Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.Active, not recruitingNCT06248528Lead (inferred)N/AStart 2019-12
  48. Anatomy-based Resection or Margin-based Resection for Hepatocellular CarcinomaStatus unknownNCT03652896Lead (inferred)N/AStart 2019-01
  49. A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular CarcinomaCompletedNCT05117047Lead (inferred)Start 2015-02
  50. Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad ClampingStatus unknownNCT02405416Lead (inferred)N/AStart 2015-03
  51. Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During HepatectomyStatus unknownNCT02319863Lead (inferred)N/AStart 1994-02
  52. cfDNA Methylation for Liver Cancer Recurrence DetectionRecruitingNCT07466602Study siteStart 2025-09
  53. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  54. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  55. Phase 2 Study of WGI-0301 for Advanced HCCRecruitingNCT06309485Study sitePhase 2Start 2024-07
  56. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  57. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  58. A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC PatientsEnrolling by invitationNCT05441475Study sitePhase 2Start 2021-12
  59. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  60. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver CancerWithdrawnNCT05292443Study siteStart 2021-12
  61. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  62. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  63. Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Study sitePhase 2Start 2020-01
  64. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  65. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  66. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  67. Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Study sitePhase 2Start 2019-12
  68. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  69. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  70. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular CarcinomaCompletedNCT01717066Study siteN/AStart 2012-11
  71. Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical HepatectomyTerminatedNCT01760616Study sitePhase 4Start 2011-11
  72. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical HepatectomyCompletedNCT01770431Study sitePhase 4Start 2011-08
  73. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 45 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
45
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 101020212022: 4420222023: 111120232024: 101020242025: 10102025

5 hospitals in Wuhan for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 12

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07078136

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06597227

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  3. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  4. Recruiting
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT06413212

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  6. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  7. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  8. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  9. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  10. Recruiting
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05687357

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan

  11. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  12. Not yet recruiting
    A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07233850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIChemotherapy & combined treatment
Departments in papersMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led45
  1. Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Effects of Thymidine Phosphorylase and Sine Oculis Homeobox Homologue 1 on the Prognosis and Immune Microenvironment of Gastric Cancer.2025Current medical science
  3. Exploring the effect of capsaicin on gene expression and chemotherapy sensitization in gastric cancer cells.2025European journal of medical researchFree full text
  4. The circRNA circSCAF8 promotes tumor growth and metastasis of gastric cancer via miR-1293/TIMP1signaling.2025Gene therapy
  5. Unveiling lymphocyte dynamics: Navigating postoperative immune landscapes in gastric cancer patients undergoing laparoscopic D2 gastrectomy.2025International journal of immunopathology and pharmacologyFree full text
  6. Prospective multicenter validation of a machine learning model for predicting anastomotic leakage in patients with gastric adenocarcinoma undergoing total or proximal gastrectomy.2025International journal of surgery (London, England)Free full text
  7. Survival benefit from adjuvant chemoradiotherapy in local advanced gastric cancer without accurate D2 confirmation: a real-world retrospective study (TJ-ARK01).2025PeerJFree full text
  8. Machine learning-based prediction of duodenal stump leakage following laparoscopic gastrectomy for gastric cancer.2025Surgery
  9. Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.2025The oncologistRCTFree full text
  10. Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy.2025The oncologistFree full text
  11. A Novel Nomogram to Predict Resectable Gastric Cancer Based on Preoperative Circulating Tumor Cell.2024Clinical and translational gastroenterologyFree full text
  12. Amino acid metabolism-related genes as potential biomarkers and the role of MATN3 in stomach adenocarcinoma: A bioinformatics, mendelian randomization and experimental validation study.2024International immunopharmacology
  13. Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives.2024Journal of cellular and molecular medicineFree full text
  14. Identification of histopathological classification and establishment of prognostic indicators of gastric adenocarcinoma based on deep learning algorithm.2024Medical molecular morphologyFree full text
  15. OCTA-based research on changes of retinal microcirculation in digestive tract malignancy.2024Photodiagnosis and photodynamic therapy
  16. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.2024Postgraduate medical journal
  17. The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis.2024SurgeryRCT
  18. Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  19. Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  20. Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgeryRCT
  21. PWSC: a novel clustering method based on polynomial weight-adjusted sparse clustering for sparse biomedical data and its application in cancer subtyping.2023BMC bioinformaticsFree full text
  22. The role of lncRNA SNHG14 in gastric cancer: enhancing tumor cell proliferation and migration, and mechanisms of CDH2 expression.2023Cell cycle (Georgetown, Tex.)Free full text
  23. Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China.2023Current medical science
  24. Bacterial infection and microbiota in carcinogenesis and tumor development.2023Frontiers in cellular and infection microbiologyFree full text
  25. Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China.2023Frontiers in immunologyFree full text
  26. Short-term prognostic role of peripheral lymphocyte subsets in patients with gastric cancer.2023International immunopharmacology
  27. MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis.2023International journal of biological sciencesFree full text
  28. Relationship between endoscopic gastric abnormalities and colorectal polyps: a cross-sectional study based on 33439 Chinese patients.2023International journal of medical sciencesFree full text
  29. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.2023Oncology research and treatment
  30. Collagen type V alpha 2 promotes the development of gastric cancer via M2 macrophage polarization.2023The Chinese journal of physiology
  31. Prospective Comparison of Oral Contrast-Enhanced Transabdominal Ultrasound Imaging With Contrast-Enhanced Computed Tomography in Pre-operative Tumor Staging of Gastric Cancer.2023Ultrasound in medicine & biology
  32. Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3β/MCL-1 signaling pathway.2022European journal of pharmacology
  33. Epstein-Barr Virus is Associated with Gastric Cancer Precursor: Atrophic Gastritis.2022International journal of medical sciencesFree full text
  34. Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.2022Scandinavian journal of gastroenterology
  35. Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis.2022Surgical endoscopy
  36. Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.2021BMC cancerFree full text
  37. Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer.2021Bioscience reportsFree full text
  38. Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial.2021Cell reports. MedicineRCTFree full text
  39. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.2021Current medical science
  40. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  41. Bibliometric Evaluation of Publications (2000-2020) on the Prognosis of Gastric Cancer.2021Inquiry : a journal of medical care organization, provision and financingFree full text
  42. PARP inhibitors in gastric cancer: beacon of hope.2021Journal of experimental & clinical cancer research : CRFree full text
  43. Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.2021Journal of physiology and biochemistry
  44. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.2021Pathology oncology research : PORFree full text
  45. Intussusception after reconstruction following gastrectomy for gastric cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)6
  1. [The impact of neoadjuvant immunotherapy on postoperative complications and short-term efficacy in patients with advanced gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Immunotherapy: progress and challenges of a revolutionary treatment for gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Attach importance to functional evaluation after gastric-preserving surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Rethinking the scope of lymphadenectomy after neoadjuvant immunotherapy for locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Development of membrane anatomy theory in gastric cancer surgery].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Demonstration and significance on proximal segment of dorsal mesogastrium].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status40
  1. Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor DiagnosisRecruitingNCT07078136Lead (inferred)Start 2025-07
  2. Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant TherapyRecruitingNCT06597227Lead (inferred)N/AStart 2024-03
  3. Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast CancerRecruitingNCT06199895Lead (inferred)Phase 2Start 2023-11
  4. Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity TestingRecruitingNCT06413212Lead (inferred)Start 2023-08
  5. Effect of Gastrectomy on Gut Microbiome and Cognitive FunctionStatus unknownNCT06186089Lead (inferred)Start 2024-01
  6. Comparison of pCLE and EB in Gastric Lesion DiagnosisStatus unknownNCT06389448Lead (inferred)N/AStart 2024-04
  7. The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric CancerStatus unknownNCT06592287Lead (inferred)Phase 1/Phase 2Start 2024-09
  8. Validation of a Model for Predicting Anastomotic LeakageCompletedNCT05646290Lead (inferred)Start 2022-01
  9. Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric CancerTerminatedNCT04294784Lead (inferred)Phase 2Start 2020-04
  10. The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer PrognosisCompletedNCT06697821Lead (inferred)Start 2020-05
  11. Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric AdenocarcinomaStatus unknownNCT03801668Lead (inferred)Phase 3Start 2019-03
  12. Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric CancerStatus unknownNCT03601988Lead (inferred)Phase 3Start 2018-07
  13. Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision(D2+CME)for Advanced Gastric CancerStatus unknownNCT01978444Lead (inferred)N/AStart 2014-09
  14. The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical StudyStatus unknownNCT02583659Lead (inferred)Start 2013-01
  15. Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric CancerStatus unknownNCT01197118Lead (inferred)Phase 2Start 2010-09
  16. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  18. A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersNot yet recruitingNCT07233850Study sitePhase 2Start 2025-11
  19. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  20. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  21. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  22. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04
  23. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Study sitePhase 2Start 2023-03
  24. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  25. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  26. Plasma Metabolic Biomarkers for Gastric Cancer DiagnosisCompletedNCT06109805Study siteStart 2023-10
  27. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  28. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  29. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  31. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  32. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  33. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  34. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  35. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  36. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  37. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  38. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  39. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  40. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Wuhan for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

18 hospitals in Wuhan for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Wuhan for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Competing risk nomogram for predicting prognosis of patients with spinal and pelvic chordoma: A SEER-based retrospective study.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 3320232024: 2220242025: 002025

31 hospitals in Wuhan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led12
  1. Construction and clinical validation of a machine-learning-based consensus prognostic signature (MLPS) for osteosarcoma via multi-cohort data integration.2026International immunopharmacology
  2. OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway.2024Journal of experimental & clinical cancer research : CR
  3. EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy.2024Journal of nanobiotechnology
  4. Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.2023ACS applied materials & interfaces
  5. Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.2023Journal of orthopaedic surgery and research
  6. P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization.2023Journal of translational medicine
  7. Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: a retrospective study of 118 cases.2022BMC cancer
  8. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.2022EBioMedicine
  9. Infiltration of LPAR5+ macrophages in osteosarcoma tumor microenvironment predicts better outcomes.2022Frontiers in immunology
  10. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.2022Journal of surgical oncology
  11. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.2021Cell death & disease
  12. Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values.2021Current medical science
Earlier papers (2016–2020)14
  1. Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis.2020Advanced healthcare materials
  2. Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.2020BMC cancer
  3. HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis.2020Cell transplantation
  4. Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.2020Histology and histopathology
  5. Knockdown of STIP1 inhibits the invasion of CD133‑positive cancer stem‑like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways.2020International journal of molecular medicine
  6. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.2019International journal of cancer
  7. Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study.2019International orthopaedics
  8. Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.2019Journal of cellular biochemistry
  9. Matrix stiffness regulates epithelial-mesenchymal transition via cytoskeletal remodeling and MRTF-A translocation in osteosarcoma cells.2019Journal of the mechanical behavior of biomedical materials
  10. Clinical Features and Long-Term Outcome of Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases From a Single Institution.2019World neurosurgery
  11. Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.2018Cell death & disease
  12. MMP-1 Over-expression Promotes Malignancy and Stem-Like Properties of Human Osteosarcoma MG-63 Cells In Vitro.2018Current medical science
  13. Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved.2017Current pharmaceutical design
  14. Meningeal Ewing Sarcoma/Peripheral PNET: Clinicopathological, Immunohistochemical and FISH study of four cases.2017Neuropathology : official journal of the Japanese Society of Neuropathology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

9 hospitals in Wuhan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07078136

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led3
  1. MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.2023Current medical science
  2. Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.2022Scandinavian journal of gastroenterology
  3. Current knowledge of primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature.2021The Journal of international medical research
Earlier papers (2016–2020)8
  1. Assessment of tumor heterogeneity: Differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis.2019European journal of radiology
  2. Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification.2018Cancer imaging : the official publication of the International Cancer Imaging Society
  3. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.2018Cell communication and signaling : CCS
  4. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling.2018Molecular cancer
  5. CD117 is not always positive in infantile gastrointestinal stromal tumor.2018World journal of pediatrics : WJP
  6. Imbedding pancreaticojejunostomy used in pure laparoscopic pancreaticoduodenectomy for nondilated pancreatic duct.2017Surgical endoscopy
  7. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.2016Oncotarget
  8. [Comparison of the clinical efficacy of laparoscopic wedge resection and open wedge resection for the treatment of gastrointestinal stromal tumor].2016Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status3
  1. Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor DiagnosisRecruitingNCT07078136Lead (inferred)Start 2025-07
  2. CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled StudyNot yet recruitingNCT07106411Lead (inferred)Start 2025-08
  3. A Real-world Comparison of FNB and FNA in IHC-required Lesions.CompletedNCT05565066Lead (inferred)Start 2014-12

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 8 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 552025

11 hospitals in Wuhan for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05701306

    Age 5 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsRadiology / nuclear medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Integrated bulk and single-cell RNA sequencing reveals a cuproptosis-related LncRNA prognostic signature in neuroblastoma.2025BMC cancer
  2. Identification of Crucial Genes Associated With MYCN-Driven Neuroblastoma Based on Single-Cell Analysis and Machine Learning.2025Cancer medicine
  3. Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.2025Cellular signalling
  4. Leveraging small voxel with optimal acquisition time for [18F]mFBG total-body PET/CT imaging in pediatric patients with neuroblastoma: a preliminary study.2025European journal of nuclear medicine and molecular imaging
  5. Prediction of neuroblastoma prognosis with a novel T-cell exhaustion-related gene signature.2025Scientific reports
  6. MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease.2024Journal of translational medicine
  7. NTRK1-mediated protection against manganese-induced neurotoxicity and cell apoptosis via IGF2 in SH-SY5Y cells.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Transcriptomics reveals the effects of NTRK1 on endoplasmic reticulum stress response-associated genes in human neuronal cell lines.2023PeerJ
Earlier papers (2016–2020)5
  1. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.2020Cancer medicine
  2. NBPF1 independently determine the risk stratification and prognosis of patients with neuroblastoma.2020Genomics
  3. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.2020Journal of cellular and molecular medicine
  4. Analytical validation and clinical application of urinary vanillylmandelic acid and homovanillic acid by LC-MS/MS for diagnosis of neuroblastoma.2019Biomedical chromatography : BMC
  5. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.2017Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
All its trials on ClinicalTrials.gov, any status1
  1. APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Study sitePhase 1/Phase 2Start 2023-02

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Wuhan for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
19
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 4420232024: 2220242025: 442025

3 hospitals in Wuhan for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 15

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06791681

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Registry
    NCT05219721

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  3. Not yet recruiting
    A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07376720

    Age 18 years to 78 years (registered criteria)

    Led by Tongji HospitalWuhan

  4. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  5. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  7. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  8. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  9. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  10. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  11. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  12. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  13. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  14. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  15. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyRelapse & resistanceDrug combinations
Departments in papersNeurology
Papers it led19
  1. Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.2025Cancer medicineFree full text
  2. A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.2025Cytotherapy
  3. Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.2025Journal of translational medicineFree full text
  4. Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  5. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.2024EMBO molecular medicineFree full text
  6. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy.2024Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  7. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.2023BMC cancerFree full text
  8. A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.2023Journal of translational medicineFree full text
  9. Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.2023MedicineFree full text
  10. Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.2023Thrombosis research
  11. Rare Distribution of Sclerotic Bony Lesions in Multiple Myeloma: A Case Report.2022Clinical nuclear medicine
  12. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.2022Journal for immunotherapy of cancerFree full text
  13. Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.2022The Journal of international medical researchFree full text
  14. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.2021Blood
  15. Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.2021Blood cancer journalFree full text
  16. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.2021Clinical and translational medicineFree full text
  17. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.2021Current medical science
  18. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.2021Frontiers in immunologyFree full text
  19. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status30
  1. A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of TreatmentNot yet recruitingNCT07376720Lead (inferred)N/AStart 2026-02
  2. A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple MyelomaRecruitingNCT06791681Lead (inferred)Early phase 1Start 2025-01
  3. A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05219721Lead (inferred)Phase 1Start 2022-03
  4. A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaStatus unknownNCT05201118Lead (inferred)Phase 1Start 2022-01
  5. Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#Status unknownNCT05266768Lead (inferred)Phase 1Start 2022-04
  6. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  8. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  9. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  10. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Study siteEarly phase 1Start 2026-01
  11. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  12. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  13. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  14. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  15. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  16. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  17. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  18. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Study sitePhase 1Start 2025-05
  19. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  20. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  21. Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic MalignanciesStatus unknownNCT05672420Study sitePhase 1/Phase 2Start 2023-01
  22. the Safety and Efficacy of SENL103 Autologous T Cell InjectionStatus unknownNCT06067581Study siteEarly phase 1Start 2023-08
  23. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  24. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  25. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  26. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  27. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  28. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  29. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  30. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 7 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 3.1%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 332025

3 hospitals in Wuhan for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06689917

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  4. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  5. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

  6. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenCAR-T & cell therapyAntibody & targeted drugs
Departments in papersMedical oncologyPediatrics
Papers it led7
  1. Blinatumomab in pediatric B-acute lymphoblastic leukemia.2025Frontiers in immunologyFree full text
  2. Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.2025Journal of translational medicineFree full text
  3. FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.2025Leukemia & lymphoma
  4. Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.2024Cancer medicineFree full text
  5. MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy.2023Cancer immunology, immunotherapy : CIIFree full text
  6. Functional diversification and dynamics of CAR-T cells in patients with B-ALL.2023Cell reports
  7. Upregulation of CD22 by Chidamide promotes CAR T cells functionality.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
All its trials on ClinicalTrials.gov, any status10
  1. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNCT06689917Lead sponsorN/AStart 2025-01
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  3. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  5. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.RecruitingNCT06927466Study sitePhase 1Start 2024-09
  6. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Study sitePhase 2Start 2022-01
  7. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Study sitePhase 1/Phase 2Start 2022-11
  8. Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLStatus unknownNCT04888442Study sitePhase 1Start 2020-10
  9. Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsCompletedNCT04888468Study sitePhase 1Start 2019-11
  10. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 8 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.9%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 332025

4 hospitals in Wuhan for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07552506

    Age 14 years to 50 years; women only (registered criteria)

    Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantImmunosuppressive treatmentThrombopoietin drugs
Papers it led8
  1. Alemtuzumab for haematological malignancies.2025Annals of hematologyFree full text
  2. Parvovirus B19-induced aplastic anemia following mechanical valve replacement.2025The Journal of international medical researchFree full text
  3. Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.2025Transplantation and cellular therapy
  4. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.2024Transplantation and cellular therapy
  5. An atypical patient with bone marrow failure syndrome-2 without microcephaly and learning disability in a Chinese family.2023British journal of haematology
  6. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?2022Transplantation and cellular therapy
  7. Comparisons of Modified Post-Transplantation Cyclophosphamide and Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin Regimens for Haploidentical Stem Cell Transplantation in Patients with Aplastic Anemia.2022Transplantation and cellular therapy
  8. Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience.2021Transplantation and cellular therapy
Chinese-language papers (not in the count)1
  1. [Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using GoserelinNot yet recruitingNCT07552506Study siteN/AStart 2026-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 20 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 5.0%.

Papers led
20
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 5520232024: 1120242025: 662025

2 hospitals in Wuhan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT03491605

    Age not stated (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersDiagnosis & prognosisGenetics & inherited forms
Departments in papersPathology / laboratory medicineRheumatology & immunology
Papers it led20
  1. A case of cirrhosis concurrent with NK/T-Cell lymphoma and hemophagocytic lymphohistiocytosis: a clinical report and literature review.2025BMC infectious diseasesFree full text
  2. The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDs.2025International immunopharmacology
  3. UNC13D c.2588G>A Nucleotide Variant Impairs NK-Cell Cytotoxicity in Adult-Onset EBV-Associated Hemophagocytic Lymphohistiocytosis: A Pedigree Study.2025International journal of molecular sciencesFree full text
  4. Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients.2025PLoS neglected tropical diseasesFree full text
  5. Deep insight into cytokine storm: from pathogenesis to treatment.2025Signal transduction and targeted therapyFree full text
  6. Immune profiling and prognosis implications in severe fever with thrombocytopenia syndrome with and without hemophagocytic lymphohistiocytosis.2025Travel medicine and infectious disease
  7. Comprehensive evaluation of immune dysregulation in secondary hemophagocytic lymphohistiocytosis.2024VirulenceFree full text
  8. IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.2023Frontiers in immunologyFree full text
  9. The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis.2023Immunobiology
  10. Hemophagocytic lymphohistiocytosis with a hemizygous PRF1 c.674G>A mutation.2023The American journal of the medical sciences
  11. Clinical and genetic characterization of Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases.2023The Journal of allergy and clinical immunology
  12. Clinical profile, etiology, and outcome of hemophagocytic lymphohistiocytosis associated with histiocytic necrotizing lymphadenitis.2023World journal of pediatrics : WJPFree full text
  13. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.2022Hematological oncology
  14. Tuberculosis infection related hemophagocytic lymphohistiocytosis diagnosed in patient with GZMB mutation: A case report and literature review.2022MedicineFree full text
  15. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis.2022The Journal of allergy and clinical immunologyFree full text
  16. Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis.2021Annals of hematology
  17. Clinical and genetic features of Epstein-Barr virus-triggered late-onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees study.2021Clinical and translational medicineFree full text
  18. Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.2021Clinical lymphoma, myeloma & leukemia
  19. Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19.2021Current medical scienceFree full text
  20. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms.2021European journal of human genetics : EJHGFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Surveillance and Tracking the Outcomes of Chronic Latent EBV InfectionRecruitingNCT03491605Lead (inferred)Start 2019-07
More papers found outside PubMed (not counted)6
  1. Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.2025Journal of Clinical Oncologyarticle
  2. Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial2025Bloodconference-abstract
  3. CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.2024Journal of Clinical Oncologyconference-abstract
  4. Clinical analysis of seven cases of hemophagocytic lymphohistiocytosis secondary to cutaneous T-cell lymphoma2023Chinese Journal of Dermatologyarticle
  5. Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study2023Bloodconference-abstract
  6. Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis2022Bloodarticle

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Wuhan for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Alpha and beta-Thalassemia mutations in Hubei area of China.2020BMC medical genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 4 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Wuhan for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    Phase
    Phase 3
    Started
    2022-12
    Registry
    NCT05611801

    Age 1 year to 17 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  2. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsMedical oncologyPathology / laboratory medicine
Papers it led4
  1. Investigation and Analysis of the Current Status of Health-Related Quality of Life in Adolescents with Hemophilia in Hubei Province.2024British journal of hospital medicine (London, England : 2005)
  2. Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.2024Current medical science
  3. An aberrant F8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient.2021Hematology (Amsterdam, Netherlands)
  4. TWIN BROTHERS WITH VARIABLE PHENOTYPES OF HAEMOPHILIA A RESULTING FROM MATERNAL MOSAICISM OF ARG550CYS OF F8.2021Journal of paediatrics and child health
Chinese-language papers (not in the count)1
  1. [Analysis of a patient with severe Hemophilia A due to a large duplication of F8 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)8
  1. Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. Clinical findings in a patient with haemophilia A affected by COVID-19.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Determining the cutoff value of the APTT mixing test for factor VIII inhibitor.2019Clinical chemistry and laboratory medicine
  4. F8 IVS9+5G>A mutation causes moderate haemophilia A.2019Haemophilia : the official journal of the World Federation of Hemophilia
  5. A Retrospective Analysis of Intracranial Hemorrhage in Children with Hemophilia A.2018Current medical science
  6. Performance of next-generation sequencing in the detection of large exon deletion in patients of haemophilia A.2018Haemophilia : the official journal of the World Federation of Hemophilia
  7. Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.2017Medicine
  8. [Study of gene mutation in 62 hemophilia A children].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status11
  1. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  2. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  3. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  4. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  5. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  6. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  7. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for InjectionCompletedNCT05251090Study sitePhase 1Start 2021-06
  8. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  9. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia ACompletedNCT02634723Study siteStart 2015-12
  10. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06
  11. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427Study siteStart 2011-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 6 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 9.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

1 hospital in Wuhan for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineGastroenterology / hepatology
Papers it led6
  1. Improving the PLASMIC score with the use of RDW-SD in the differential diagnosis for thrombotic thrombocytopenic purpura in Chinese patients.2026Annals of clinical biochemistry
  2. Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.2025Annals of hematology
  3. A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity.2024Seminars in thrombosis and hemostasis
  4. Identification of 8 Rare Deleterious Variants in ADAMTS13 by Next-generation Sequencing in a Chinese Population with Thrombotic Thrombocytopenic Purpura.2023Current medical science
  5. A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant.2022Seminars in thrombosis and hemostasis
  6. Thrombotic thrombocytopenic purpura complicated with acute aortic dissection: A case report.2021Medicine
Chinese-language papers (not in the count)1
  1. [Advance in the diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)2
  1. [N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura: a case report].2020Zhonghua nei ke za zhi
  2. Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.2018Thrombosis research
All its trials on ClinicalTrials.gov, any status1
  1. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 18 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 3.7%.

Papers led
18
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 6620232024: 4420242025: 112025

2 hospitals in Wuhan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07526493

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06620809

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  3. Recruiting
    Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT06885957

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  4. Recruiting
    Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06474520

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    Biomarkers in Autoimmune Disease of Nervous System
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06502015

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  6. Recruiting
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    Phase
    Early phase 1
    Started
    2020-09
    Registry
    NCT04561557

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  7. Not yet recruiting
    Tongji NADs Cohort
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07333196

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  8. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisImagingAcute attack treatment
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led18
  1. Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.2025Neurology
  2. Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.2024Brain : a journal of neurology
  3. Segmental abnormalities of white matter microstructure in multiple sclerosis and neuromyelitis optica spectrum disorder identified by automated fiber quantification.2024Multiple sclerosis and related disorders
  4. Serum LDL Promotes Microglial Activation and Exacerbates Demyelinating Injury in Neuromyelitis Optica Spectrum Disorder.2024Neuroscience bulletinFree full text
  5. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.2024Science immunology
  6. Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.2023Annals of neurology
  7. Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis.2023Frontiers in immunologyFree full text
  8. Editorial: Immune Mechanisms in white matter lesions: Clinical and pathophysiological implications.2023Frontiers in immunologyFree full text
  9. TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder.2023Journal of neuroinflammationFree full text
  10. Structural covariance in subcortical regions in multiple sclerosis and neuromyelitis optica spectrum disorders: An MRI-based study with automated brain volumetry.2023Multiple sclerosis and related disorders
  11. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.2023Signal transduction and targeted therapyFree full text
  12. Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis.2022European radiology
  13. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation.2022Multiple sclerosis and related disorders
  14. Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System.2022Neuroimmunomodulation
  15. Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?2021Frontiers in immunologyFree full text
  16. Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review.2021Frontiers in immunologyFree full text
  17. Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder.2021Journal of neuroinflammationFree full text
  18. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.2021Multiple sclerosis and related disorders
All its trials on ClinicalTrials.gov, any status9
  1. Tongji NADs CohortNot yet recruitingNCT07333196Lead sponsorStart 2026-03
  2. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.RecruitingNCT07526493Lead sponsorPhase 1Start 2026-04
  3. Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDRecruitingNCT06885957Lead sponsorStart 2025-07
  4. The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersRecruitingNCT06620809Lead sponsorPhase 1Start 2025-03
  5. Biomarkers in Autoimmune Disease of Nervous SystemRecruitingNCT06502015Lead sponsorStart 2024-07
  6. Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)RecruitingNCT06474520Lead sponsorN/AStart 2024-08
  7. Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemRecruitingNCT04561557Lead sponsorEarly phase 1Start 2020-09
  8. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  9. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
More papers found outside PubMed (not counted)3
  1. A Real-World Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder (P11-8.012)2025Neurologyarticle
  2. Anti-BCMA CAR T-CELL therapy CT103A in relapsed or refractory AQP4-IGG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results2023Journal of the Neurological Sciencesarticle
  3. Contribution of clinical attacks to the irreversible disability in NMOSD (S50.007)2023Neurologyarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 11 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.5%.

Papers led
11
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 6620222023: 1120232024: 0020242025: 332025

2 hospitals in Wuhan for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497361

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497387

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  3. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis & look-alikesTreatment & relapseHead, eye socket & salivary glands
Departments in papersRheumatology & immunologyRadiology / nuclear medicine
Papers it led11
  1. Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.2025Annals of the rheumatic diseasesRCT
  2. Omics in IgG4-related disease.2025Chinese medical journalFree full text
  3. Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.2025Journal of proteome research
  4. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.2023Annals of the rheumatic diseasesFree full text
  5. Clinical value of 18F-FDG PET/CT in IgG4-related disease.2022Annals of nuclear medicine
  6. Update on classification, diagnosis, and management of immunoglobulin G4-related disease.2022Chinese medical journalFree full text
  7. Role of eosinophilia in IgG4-related disease.2022Clinical and experimental rheumatology
  8. Multi-System Langerhans Cell Histiocytosis as a Mimic of IgG4-Related Disease: A Case Report and Literature Review.2022Frontiers in endocrinologyFree full text
  9. Proteomic characteristics of saliva in patients with different subgroups of IgG4-RD.2022Frontiers in immunologyFree full text
  10. Potential roles of non-lymphocytic cells in the pathogenesis of IgG4-related disease.2022Frontiers in immunologyFree full text
  11. IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases.2021Current medical science
All its trials on ClinicalTrials.gov, any status5
  1. Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497387Lead sponsorEarly phase 1Start 2024-07
  2. Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497361Lead sponsorEarly phase 1Start 2024-07
  3. the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune DiseasesActive, not recruitingNCT07339540Lead sponsorEarly phase 1Start 2025-11
  4. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  5. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01
More papers found outside PubMed (not counted)4
  1. Potential roles of antibodies with different classes in IgG4‐related diseases2025Rheumatology & autoimmunityarticle
  2. Case Report: A Rare Manifestation of IgG4 ‐Related Disease: Isolated Hepatocellular Injury2024International Journal of Rheumatic Diseasesarticle
  3. POS0347 INSIGHTS INTO THE DESIGN AND STUDY POPULATION OF MITIGATE: THE FIRST MULTINATIONAL RANDOMIZED CONTROLLED CLINICAL TRIAL IN IgG4 RELATED DISEASE (IgG4-RD), EVALUATING THE EFFICACY AND SAFETY OF INEBILIZUMAB2024Annals of the Rheumatic Diseasesconference-abstract
  4. IgG4-Related Disease2023Springer eBooksbook-chapter

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 17 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.4%.

Papers led
17
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 5520232024: 4420242025: 442025

3 hospitals in Wuhan for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07526493

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  2. Recruiting
    GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07058298

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  3. Recruiting
    CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07337785

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  4. Recruiting
    Biomarkers in Autoimmune Disease of Nervous System
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06502015

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    Phase
    Early phase 1
    Started
    2020-09
    Registry
    NCT04561557

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  6. Not yet recruiting
    Tongji NADs Cohort
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07333196

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  7. Not yet recruiting
    Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07714798

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  8. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2026-12
    Registry
    NCT07917923

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  9. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStandard immunotherapyThymus & thymectomyAntibodies & diagnosis
Departments in papersNeurology
Papers it led17
  1. Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report.2025BMC neurologyFree full text
  2. The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis.2025Cellular immunology
  3. The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.2025Muscle & nerve
  4. Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Type B thymomas in patients with myasthenia gravis display a distinctive pattern of αβ TCR and IL-7 receptor α expression on CD4+CD8+ thymocytes.2024Autoimmunity
  6. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.2024EMBO molecular medicineFree full text
  7. Exhausted signature and regulatory network of NK cells in myasthenia gravis.2024Frontiers in immunologyFree full text
  8. Effect of thymectomy on the frequencies of peripheral regulatory B and T lymphocytes in patients with Myasthenia gravis-a pilot study.2024The International journal of neuroscience
  9. Development and validation of the scale for symptom clusters in patients with myasthenia gravis.2023BMC neurologyFree full text
  10. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.2023Frontiers in immunologyFree full text
  11. Effects of symptom clusters on quality of life mediated by self-efficacy among individuals with myasthenia gravis: A structural equation modelling analysis.2023Journal of clinical nursing
  12. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
  13. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.2023Pediatric neurology
  14. Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation.2022European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur KinderchirurgieFree full text
  15. Subxiphoid-subcostal thoracoscopic thymectomy for seropositive myasthenia offers equivalent remission rates and potentially faster recovery.2022Interactive cardiovascular and thoracic surgeryFree full text
  16. Differences in immunophenotypes between myasthenia gravis patients with and without thyroid antibodies.2022Muscle & nerve
  17. Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.2021Cell biology internationalFree full text
All its trials on ClinicalTrials.gov, any status13
  1. Tongji NADs CohortNot yet recruitingNCT07333196Lead sponsorStart 2026-03
  2. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.RecruitingNCT07526493Lead sponsorPhase 1Start 2026-04
  3. CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesRecruitingNCT07337785Lead sponsorEarly phase 1Start 2025-12
  4. Biomarkers in Autoimmune Disease of Nervous SystemRecruitingNCT06502015Lead sponsorStart 2024-07
  5. Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemRecruitingNCT04561557Lead sponsorEarly phase 1Start 2020-09
  6. Universal STAR-T Cell Injection in Generalized Myasthenia GravisNot yet recruitingNCT07714798Lead (inferred)Phase 1Start 2026-07
  7. A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT07917923Lead (inferred)Early phase 1Start 2026-12
  8. GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)RecruitingNCT07058298Lead (inferred)Early phase 1Start 2025-07
  9. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  10. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  11. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09
  12. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  13. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

3 hospitals in Wuhan for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Treatment of Moyamoya Disease With iPSC-derived Exosomes
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07065409

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomes
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 2 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Wuhan for biliary atresia28 hospitals in China for biliary atresia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Nutritional Intervention for Biliary Atresia
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT06764082

    Age 1 day to 3 months (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesKasai operationLong-term outcomesDisease mechanisms
Departments in papersPediatrics
Papers it led2
  1. Efficacy of sodium bicarbonate Ringer's solution for perioperative fluid management in infants with biliary atresia: a prospective multicenter study.2025Pediatric surgery international
  2. Mechanism of biliary atresia caused by T follicular helper cells-induced immune injury.2024BMC pediatricsFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Nutritional Intervention for Biliary AtresiaRecruitingNCT06764082Lead sponsorN/AStart 2025-02
  2. Antibiotics Treatment of Cholangitis Post-Kasai PortoenterostomyCompletedNCT04370145Lead sponsorPhase 4Start 2021-05
More papers found outside PubMed (not counted)2
  1. Liver transplantation2024Elsevier eBooksbook-chapter
  2. Pregnancy after organ transplantation2024Elsevier eBooksbook-chapter

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

5 hospitals in Wuhan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 14 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.4%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 4420242025: 332025

9 hospitals in Wuhan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led14
  1. Associations between dietary patterns and the incidence of idiopathic pulmonary fibrosis: A cohort study.2026The journal of nutrition, health & aging
  2. Semaphorin 3E-Plexin D1 Axis Drives Lung Fibrosis through ErbB2-Mediated Fibroblast Activation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Targeting PBK in the fibroblast-to-myofibroblast transition: A novel therapeutic strategy for IPF.2025Biochemical pharmacology
  4. Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53.2025International immunopharmacology
  5. Alpinetin ameliorates bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk.2024International journal of nanomedicine
  7. Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [18F]ATX-1905.2024Molecular pharmaceutics
  8. Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.2024Respiratory research
  9. Lung Transplantation: A Viable Option for Connective Tissue Disease?2023Arthritis care & research
  10. Genetic Programs Between Steroid-Sensitive and Steroid-Insensitive Interstitial Lung Disease.2023Inflammation
  11. The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis.2023Medicina (Kaunas, Lithuania)
  12. The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.2022The European respiratory journal
  13. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.2021Journal of clinical laboratory analysis
  14. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.2021Theranostics
Earlier papers (2016–2020)10
  1. Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Response.2020Chest
  3. Response.2020Chest
  4. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.2020Chest
  5. Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis.2020Experimental lung research
  6. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.2020Oncoimmunology
  7. Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation.2020Respiratory research
  8. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.2019Cell death & disease
  9. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis.2018Human mutation
  10. Macrophages: friend or foe in idiopathic pulmonary fibrosis?2018Respiratory research
All its trials on ClinicalTrials.gov, any status8
  1. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  2. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  3. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis SubjectsCompletedNCT05895565Study sitePhase 1Start 2023-05
  4. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  5. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  6. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  7. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  8. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Wuhan for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 11 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.4%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 3320242025: 442025

6 hospitals in Wuhan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06849609

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led11
  1. Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis.2025Aging and disease
  2. White matter integrity mediated the effect of plasma uric acid levels on cognitive function in ALS patients.2025Brain imaging and behavior
  3. Association between cardiac autonomic dysfunction, cognitive impairment, and survival in patients with amyotrophic lateral sclerosis.2025Clinical autonomic research : official journal of the Clinical Autonomic Research Society
  4. Astrocytes Contribute to Motor Neuron Degeneration in ALS via the TRAIL-DR5 Signaling Pathway.2025Journal of neurochemistry
  5. Association between apathy and caregiver burden in patients with amyotrophic lateral sclerosis: a cross-sectional study.2024BMJ open
  6. Quantitative MRI Analysis of Brachial Plexus and Limb-Girdle Muscles in Upper Extremity Onset Amyotrophic Lateral Sclerosis.2024Journal of magnetic resonance imaging : JMRI
  7. Brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling in spinal muscular atrophy and amyotrophic lateral sclerosis.2024Neurobiology of disease
  8. The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  10. Decreased blood CD4+ T lymphocyte helps predict cognitive impairment in patients with amyotrophic lateral sclerosis.2021BMC neurology
  11. The illness experience for people with amyotrophic lateral sclerosis: A qualitative study.2021Journal of clinical nursing
Earlier papers (2016–2020)3
  1. Region-specific atrophy of precentral gyrus in patients with amyotrophic lateral sclerosis.2018Journal of magnetic resonance imaging : JMRI
  2. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells.2018Stem cell research & therapy
  3. Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo.2017Stem cell reports
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALSRecruitingNCT06849609Lead (inferred)Early phase 1Start 2025-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wuhan for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Wuhan for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Wuhan for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

3 hospitals in Wuhan for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 21 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 2.9%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 3320232024: 2220242025: 882025

8 hospitals in Wuhan for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPediatricsRadiology / nuclear medicine
Papers it led21
  1. Prognosis and predictive factors in pediatric IgA nephropathy.2026Pediatric nephrology (Berlin, Germany)
  2. Identifying the potential therapeutic targets of tertiary lymphoid structure in IgA nephropathy based on bioinformatics.2025Autoimmunity
  3. Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.2025BMC nephrology
  4. Network Pharmacological Analysis of Hydroxychloroquine Intervention in the Treatment of Iga Nephropathy.2025Current pharmaceutical design
  5. Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.2025Drug design, development and therapy
  6. Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center.2025Drug design, development and therapy
  7. Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.2025JMIR medical informatics
  8. Exploring the Relationship Between 91 Inflammatory Cytokines and IgA Nephropathy Using a Two-Sample Mendelian Randomization Study and the Gene Expression Omnibus Database.2025Mediators of inflammation
  9. Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.2025Pediatric rheumatology online journal
  10. Circulating soluble CD30 is associated with renal tertiary lymphoid structures and the progression of IgA nephropathy.2024Clinica chimica acta; international journal of clinical chemistry
  11. Exploring the causal effect of complement and IgA nephropathy-a Mendelian randomization study.2024Renal failure
  12. High Renal Mast Cell Density Is Associated with Poor Prognosis in Patients with Immunoglobulin A Nephropathy.2023American journal of nephrology
  13. T Follicular Helper Cells in Tertiary Lymphoid Structure Contribute to Renal Fibrosis by IL-21.2023International journal of molecular sciences
  14. Noninvasive Assessment of the Renal Function, Oxford Classification and Prognostic Risk Stratification of IgAN by Using Intravoxel Incoherent Motion Diffusion-Weighted Imaging and Blood Oxygenation Level-Dependent MRI.2023Journal of magnetic resonance imaging : JMRI
  15. Shrunken Pore Syndrome Is Associated with Renal Function Decline in Female Patients with Kidney Diseases.2022BioMed research international
  16. Clinical and Pathological Implications of Increases in Tonsillar CD19+CD5+ B Cells, CD208+ Dendritic Cells, and IgA1-positive Cells of Immunoglobulin A Nephropathy.2022Current medical science
  17. CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis.2022International journal of biological sciences
  18. Interleukin-7 Is Associated with Clinical and Pathological Activities in Immunoglobulin A Nephropathy and Protects the Renal Proximal Tubule Epithelium from Cellular Fibrosis.2021Current medical science
  19. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy.2021Histopathology
  20. The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy.2021International urology and nephrology
  21. Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A.2021Theranostics
Chinese-language papers (not in the count)1
  1. [Prognosis and risk factors of IgA vasculitis nephritis in children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)6
  1. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report.2020BMC nephrology
  2. High renal DC-SIGN+ cell density is associated with severe renal lesions and poor prognosis in patients with immunoglobulin A nephropathy.2019Histopathology
  3. Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy.2019Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  4. Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy.2018Medicine
  5. [Clinical efficacy of tonsillectomy in renal transplant patients with recurrent IgA nephropathy].2018Zhonghua yi xue za zhi
  6. Decreased DACH1 expression in glomerulopathy is associated with disease progression and severity.2016Oncotarget
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA NephropathyNot yet recruitingNCT06528015Lead (inferred)Phase 4Start 2024-07
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhan for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhan for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Aberrant activation of Cdc2/cyclin B1 is involved in initiation of cytoskeletal pathology in murine Niemann-Pick disease type C.2017Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wuhan for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Study sitePhase 3Start 2024-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

5 hospitals in Wuhan for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 13 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 8.1%.

Papers led
13
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 3320232024: 2220242025: 332025

3 hospitals in Wuhan for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Over half of these papers are lab or animal studies.

Papers it led13
  1. Analysis of the causes of redo pull-through for recurrent constipation and the risk factors affecting the prognosis of the Hirschsprung's disease: a single-center retrospective study and systematic review.2025BMC pediatrics
  2. EMB is essential for enteric nervous system development mediated by PI3K signaling.2025Genome medicine
  3. Rare and common genetic variants underlying the risk of Hirschsprung's disease.2025Human molecular genetics
  4. Identification of signaling pathways that specify a subset of migrating enteric neural crest cells at the wavefront in mouse embryos.2024Developmental cell
  5. Mesenchymal Stem Cells Attenuates Hirschsprung diseases - Associated Enterocolitis by Reducing M1 Macrophages Infiltration via COX-2 Dependent Mechanism.2024Journal of pediatric surgery
  6. Screening of undernutrition in children with Hirschsprung disease using preoperative anthropometric parameters: A multicenter cross-sectional study.2023JPEN. Journal of parenteral and enteral nutrition
  7. Abnormally elevated expression of ACTA2 of circular smooth muscle leads to hyperactive contraction in aganglionic segments of HSCR.2023Pediatric surgery international
  8. Comprehensive characterization of the genetic landscape of familial Hirschsprung's disease.2023World journal of pediatrics : WJP
  9. Identification and validation of the common pathogenesis and hub biomarkers in Hirschsprung disease complicated with Crohn's disease.2022Frontiers in immunology
  10. Down-Regulation of Double C2 Domain Alpha Promotes the Formation of Hyperplastic Nerve Fibers in Aganglionic Segments of Hirschsprung's Disease.2022International journal of molecular sciences
  11. Transanal full-thickness pull-through approach in the treatment of anastomotic leakage after operation for Hirschsprung disease.2022Pediatric surgery international
  12. NOX5 is expressed aberrantly but not a critical pathogenetic gene in Hirschsprung disease.2021BMC pediatrics
  13. Benzophenone-3 induced abnormal development of enteric nervous system in zebrafish through MAPK/ERK signaling pathway.2021Chemosphere
Earlier papers (2016–2020)12
  1. Long-term outcomes of single-incision laparoscopic technique in Soave procedure compared with heart-shaped anastomosis for Hirschsprung disease.2020International journal of colorectal disease
  2. Long-term outcomes of laparoscope-assisted heart-shaped anastomosis for children with hirschsprung disease: A 10-year review study.2020Journal of pediatric surgery
  3. Thyroid Hormone in the Pathogenesis of Congenital Intestinal Dysganglionosis.2020Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  4. Optimal time for single-stage pull-through colectomy in infants with short-segment Hirschsprung disease.2019International journal of colorectal disease
  5. Results of rectoanal manometry after a novel laparoscopic technique: laparoscope-assisted heart-shaped anastomosis for Hirschsprung's disease.2019Pediatric surgery international
  6. A Long-Term Follow-Up of a New Surgery Method: Laparoscope-Assisted Heart-Shaped Anastomosis for Hirschsprung's Disease.2018Journal of laparoendoscopic & advanced surgical techniques. Part A
  7. Diagnostic value of the preoperatively detected radiological transition zone in Hirschsprung's disease.2017Pediatric surgery international
  8. A de novo deletion mutation in SOX10 in a Chinese family with Waardenburg syndrome type 4.2017Scientific reports
  9. Novel Insights into the Pathogenesis of Hirschsprung's-associated Enterocolitis.2016Chinese medical journal
  10. Laparoscopy-assisted versus transabdominal reoperation in Hirschprung's disease for residual aganglionosis and transition zone pathology after transanal pull-through.2016Journal of pediatric surgery
  11. Single-incision laparoscopic versus conventional laparoscopic surgery for Hirschsprung's disease: A comparison of medium-term outcomes.2016Journal of pediatric surgery
  12. Pathological changes of interstitial cells of Cajal and ganglion cells in the segment of resected bowel in Hirschsprung's disease.2016Pediatric surgery international
All its trials on ClinicalTrials.gov, any status5
  1. Nutrition Support for Hirschsprung DiseaseCompletedNCT04598841Lead sponsorN/AStart 2021-01
  2. A Trial on Treatments of Hirschsprung Allied DiseaseStatus unknownNCT02212054Lead sponsorN/AStart 2020-05
  3. Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's DiseaseCompletedNCT02234219Lead sponsorN/AStart 2019-11
  4. Fast-track Surgery in the Treatment of Hirschsprung's DiseaseStatus unknownNCT02350088Lead sponsorN/AStart 2014-01
  5. A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective StudyStatus unknownNCT02216994Lead sponsorN/AStart 2013-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhan for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Wuhan for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.2022Orphanet journal of rare diseases
All its trials on ClinicalTrials.gov, any status3
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07
  3. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Wuhan for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 2 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 3.9%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Wuhan for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led2
  1. Clinical follow-up investigation on thickness changes in the peripapillary retinal nerve fibre layer of patients with Leber hereditary optic neuropathy.2024BMC ophthalmology
  2. Characterisation of thickness changes in the peripapillary retinal nerve fibre layer in patients with Leber's hereditary optic neuropathy.2021The British journal of ophthalmology
Earlier papers (2016–2020)10
  1. Factors associated with rapid improvement in visual acuity in patients with Leber's hereditary optic neuropathy after gene therapy.2020Acta ophthalmologica
  2. Multilocus Mitochondrial Mutations Do Not Directly Affect the Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy.2020Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  3. Seven-Year Follow-up of Gene Therapy for Leber's Hereditary Optic Neuropathy.2020Ophthalmology
  4. What are the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy: a prospective single-centre study in China.2019BMJ open
  5. Clinical Observation of Patients with Leber's Hereditary Optic Neuropathy Before Gene Therapy.2018Current gene therapy
  6. Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients.2018Methods in molecular biology (Clifton, N.J.)
  7. Visual Field Variability after Gene Therapy for Leber's Hereditary Optic Neuropathy.2018Ophthalmic research
  8. Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.2016EBioMedicine
  9. Evaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial.2016Medicine
  10. Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.2016Scientific reports
All its trials on ClinicalTrials.gov, any status2
  1. A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic NeuropathyStatus unknownNCT03153293Lead (inferred)Phase 2/Phase 3Start 2017-12
  2. Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)CompletedNCT01267422Lead (inferred)N/AStart 2011-04

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

华中科技大学同济医学院附属同济医院

Tongji Hospital

武汉

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Tongji Hospital; Tongji Hospital of Tongji Medical College; Affiliated Tongji Hospital; Tongji Hospital Affiliated to Tongji Medical College; Sino-French Branch of Tongji Hospital of Tongji Medical College; Tongji Hospital Affiliated with Tongji Medical College; Tongji Hospital Affiliated to Tongji Medical College of Huazhong; Huazhong University of Science and Technology

Suggest a correctionDownload the data